I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2020 & 2027

Table 3: World Current & Future Analysis for Circulating Cell
Free DNA (ccfDNA) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 4: World 7-Year Perspective for Circulating Cell Free DNA
(ccfDNA) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2020 & 2027

Table 5: World Current & Future Analysis for Circulating Tumor
Cells (CTCs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 6: World 7-Year Perspective for Circulating Tumor Cells
(CTCs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2020 & 2027

Table 7: World Current & Future Analysis for Exosomes /
Extracellular Vesicles by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World 7-Year Perspective for Exosomes / Extracellular
Vesicles by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2020 & 2027

Table 9: World Current & Future Analysis for Circulating Cell
Free RNA (ccfRNA) / miRNA by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 10: World 7-Year Perspective for Circulating Cell Free
RNA (ccfRNA) / miRNA by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2020 & 2027

Table 11: World Current & Future Analysis for Research by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 12: World 7-Year Perspective for Research by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 13: World Current & Future Analysis for Diagnostics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 14: World 7-Year Perspective for Diagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 15: USA Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 16: USA 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 17: USA Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 18: USA 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2020 &
2027

CANADA
Table 19: Canada Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 20: Canada 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 21: Canada Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 22: Canada 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2020 & 2027

JAPAN
Table 23: Japan Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 24: Japan 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 25: Japan Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 26: Japan 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2020 &
2027

CHINA
Table 27: China Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 28: China 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 29: China Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 30: China 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2020 &
2027

EUROPE
Table 31: Europe Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 32: Europe 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Geographic Region -
Percentage Breakdown of Value Sales for France, Germany, Italy,
UK and Rest of Europe Markets for Years 2020 & 2027

Table 33: Europe Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 34: Europe 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 35: Europe Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 36: Europe 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2020 & 2027

FRANCE
Table 37: France Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: France 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 39: France Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 40: France 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2020 & 2027

GERMANY
Table 41: Germany Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 42: Germany 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 43: Germany Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 44: Germany 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2020 & 2027

ITALY
Table 45: Italy Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 46: Italy 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 47: Italy Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 48: Italy 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2020 &
2027

UNITED KINGDOM
Table 49: UK Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells
(CTCs), Exosomes / Extracellular Vesicles and Circulating Cell
Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: UK 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 51: UK Current & Future Analysis for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Research and
Diagnostics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 52: UK 7-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2020 &
2027

REST OF EUROPE
Table 53: Rest of Europe Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 54: Rest of Europe 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 55: Rest of Europe Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 56: Rest of Europe 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2020 & 2027

ASIA-PACIFIC
Table 57: Asia-Pacific Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 58: Asia-Pacific 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 59: Asia-Pacific Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 60: Asia-Pacific 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2020 & 2027

REST OF WORLD
Table 61: Rest of World Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: Rest of World 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2020 & 2027

Table 63: Rest of World Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 64: Rest of World 7-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 32